WOAH Reference Laboratory Reports Activities 2023

Activities in 2023

This report has been submitted : 7 juin 2024 04:13

Laboratory Information

Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Infection with epizootic haematopoietic necrosis virus
Address of laboratory:	CSIRO Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong VIC 3220 Australia
Tel.:	+61-3 52 27 57 49
E-mail address:	moo310@csiro.au
Website:	https://www.csiro.au/en/about/facilities-collections/ACDP/Aquatic-Animal-Health
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Debbie Eagles, Director, Australian Centre for Disease Preparedness
Name (including Title and Position) of WOAH Reference Expert:	Dr Nick Moody, Research Group Leader, ACDP Fish Diseases Laboratory
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
Direct diagnostic tests		Nationally	Internationally
WOAH Ranavirus qPCR (Method 1)		31	0
EHNV 56 Genotyping PCR		27	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAH MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Gamma-irradiated EHNV tissue culture supernatant	Molecular tests	Provided	0	2 x 500uL	1	HONG KONG,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAH Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

Yes

NAME OF THE WOAH MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
DENMARK	Development, evaluation and validation EHNV-specific real-time PCR assays.	Email, videoconference
CANADA	Development, evaluation and validation EHNV-specific real-time PCR assays.	Email, videoconference, face-to-face

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Development of an ENHV-specific real-time PCR	March 2023 to ongoing	Development, evaluation and validation EHNV-specific real-time PCR assays	EURL for Finfish Diseases, Technical University of Denmark	DENMARK
Development of an ENHV-specific real-time PCR	February 2023 to ongoing	Development, evaluation and validation EHNV-specific real-time PCR assays.	Pacific Biological Station – Aquatic Animal Health Laboratory, Fisheries and Oceans Canada	CANADA

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAH?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

0

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

0

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025	PDF	NATA ISO 17025 SEP 2022.pdf
ISO17043	PDF	NATA ISO 17043 NOV 2022.pdf
ISO9001	PDF	BSI ISO 9001 NOV 2022.pdf
ISO14001	PDF	BSI ISO 14001 NOV 2022.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Virus isolation	National Association of Testing Authorities (NATA, ILAC affliated)

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory has a dedicated Biorisk Management Team (14 Members) who provide specialist advice, monitor and improve Biosafety, Biosecurity and Biocontainment activities and perform maintenance on Biocontainment systems. The team uses a risk analysis approach to management of biological risks for biosafety and biosecurity to inform and determine the policy and procedures that in turn give confidence that the laboratory procedures for each of the biological materials handled by the laboratory pose negligible danger to Australia's animal and human populations. 261 Policies and procedures are contained in the annually reviewed ACDP Biorisk Manual consisting of various sections as follows. Section 1 Administration Section 2 PC2 Procedures and Policies Section 3 PC3 Procedures and Policies Section 4 PC4 Procedures and Policies Section 5 Large Animal Facility (LAF) Procedures and Policies Section 6 Personnel and Procedural Controls Section 7 Transport and Storage of Biological Material Section 8 Movement of Material, Equipment and Waste Section 9 Engineering Procedures and Polices Section 10 Microbiological Incident Response Procedures and Policies Section 11 Laboratory Services Group Section 12 Containment Services Group The successful ACDP biological risk management system has clear and unequivocal commitment by laboratory management, who ensure that roles, responsibilities, resources and authorities related to biological risk management are defined, documented, and communicated to those who manage, perform, and verify work associated with biological agents and toxins in the laboratory. The Biorisk Management Team are audited over 3 days every 6 months by an external security assessment team to provide an independent review of elements affecting ACDP's microbiological and physical security

operations and to advise CSIRO senior executive management of any areas of concern or risk. The laboratory is aspiring to become accredited to ISO 35001:2019 Biorisk management for laboratories and other related organisations.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOAH Reference Laboratory designated for the disease

24. Do you network (collaborate or share information) with other WOAH Reference Laboratories designated for the same pathogen?

Not applicable (Only WOAH Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen?

Not applicable (Only WOAH Reference Laboratory designated for the disease)

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only WOAH Reference Laboratory designated for the disease)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons1	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the Test	WOAH Member Countries
Determining a laboratory's capability to conduct specific diagnostic tests,	Participant	44	EURL Inter-laboratory Proficiency Test 2023	DENMARK,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAH?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Invited participant	Busan, Republic of Korea, June 26 to 28, 2023	Regional Workshop for WOAH Focal Points for Aquatic Animals
Invited participant	Busan, Republic of Korea, 29 June 2023	4th meeting of ad hoc Steering Committee of Regional Collaboration Framework on Aquatic Animal Health in Asia and the Pacific
Facilitator	Pretoria, South Africa, 5 - 7 December 2023	Establishment of a Regional Aquatic Animal Health Laboratory Network (RAAHLN) for Africa

29. Additional comments regarding your report:

Yes

Regarding Point 3. "Did your laboratory supply standard reference reagents (non-WOAH-approved) and/or other diagnostic reagents to WOAH Members?" – I only include EHNV reagents here but we have also supplied positive control material for TiLV, SVCV and CEV. Would you like these to also be included in future Annual Reports?